This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Linder, L. Articles by Haefeli, W. E. Search for Related Content PubMed PubMed Citation Articles by Linder, L. Articles by Haefeli, W. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB PHENYLEPHRINE

(Hypertension. 1996;28:483-487.)
© 1996 American Heart Association, Inc.

Articles

Subconstrictor Doses of Neuropeptide Y Potentiate ₁-Adrenergic Venoconstriction In Vivo

Lilly Linder; Brigitte M. Lautenschlager; Walter E. Haefeli

the Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Basel (Switzerland).

Correspondence to Walter E. Haefeli, MD, Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland. E-mail haefeli@ubaclu.unibas.ch.

The 36–amino acid human neuropeptide Y is a vasoactive compound released after stimulation of the sympathetic nervous system. In addition to its direct and long-lasting vasopressor effects, it may potentiate the constrictor action of catecholamines and other vasoconstrictors at doses that do not per se exert vascular effects. Using the hand vein compliance technique, we have previously shown that neuropeptide Y also constricts superficial hand veins and that its effects may last for several hours. In this study, we investigated the local effect of neuropeptide Y on ₁-adrenergic venoconstriction in nine healthy volunteers at dose rates that did not affect venous compliance. On separate days, cumulative dose-response curves to phenylephrine alone and with coadministration of 1 or 30 pmol neuropeptide Y per minute were constructed, and the responses were fitted to a four-parameter logistic equation. Neuropeptide Y dose dependently shifted the phenylephrine curves toward lower dose rates without affecting maximal effects. ED₅₀ values for phenylephrine alone and with 1 or 30 pmol/min neuropeptide Y were 4.0, 4.9 (P=NS versus control), and 1.2 (P<.005) nmol/min, respectively. Comparison with neuropeptide Y dose-response curves revealed that the interaction was synergistic. These are the first data in humans to show that small dose rates of neuropeptide Y may potentiate -adrenergic effects in vivo. Because this interaction occurs at estimated local concentrations nearly achieved in humans, these studies suggest that neuropeptide Y might modulate the filling of this capacitance system in vivo.

Key Words: adrenergic receptor agonists • neuropeptides • vasoconstriction • human

This article has been cited by other articles:

				G. J. Hodges, D. N. Jackson, L. Mattar, J. M. Johnson, and J. K. Shoemaker Neuropeptide Y and neurovascular control in skeletal muscle and skin Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2009; 297(3): R546 - R555. [Abstract] [Full Text] [PDF]

				M. Lindenberger and T. Lanne Sex-related effects on venous compliance and capillary filtration in the lower limb Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R852 - R859. [Abstract] [Full Text] [PDF]

				K. D. Monahan and C. A. Ray Gender affects calf venous compliance at rest and during baroreceptor unloading in humans Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H895 - H901. [Abstract] [Full Text] [PDF]

				L. Gullestad, T. Bjuro, L. Aaberge, T. Apelland, R. Skardal, E. Kjekshus, M. Nordlander, B. Ablad, and J. Pernow The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris Eur. Heart J., June 2, 2003; 24(12): 1120 - 1127. [Abstract] [Full Text] [PDF]

				R. Freeman, V. Lirofonis, W. B. Farquhar, and M. Risk Limb venous compliance in patients with idiopathic orthostatic intolerance and postural tachycardia J Appl Physiol, August 1, 2002; 93(2): 636 - 644. [Abstract] [Full Text] [PDF]

				H. Olsen, E. Vernersson, and T. Lanne Cardiovascular response to acute hypovolemia in relation to age. Implications for orthostasis and hemorrhage Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H222 - H232. [Abstract] [Full Text] [PDF]

				L. V. Schuerch, L. M. Linder, E. Grouzmann, and W. E. Haefeli Human neuropeptide Y potentiates alpha 1-adrenergic blood pressure responses in vivo Am J Physiol Heart Circ Physiol, September 1, 1998; 275(3): H760 - H766. [Abstract] [Full Text] [PDF]

				H. Olsen and T. Lanne Reduced venous compliance in lower limbs of aging humans and its importance for capacitance function Am J Physiol Heart Circ Physiol, September 1, 1998; 275(3): H878 - H886. [Abstract] [Full Text] [PDF]